论文部分内容阅读
A new compound 8-chloro-7-(4-(3-chloropropanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid(II, C_(20)H_(20)Cl_2FN_3O_4, Mr = 456.08) was synthesized and characterized by 1H NMR, 13 C NMR, HR MS and single-crystal X-ray diffraction. X-ray powder diffraction(XRPD), thermal stabilities, UV-Vis spectrum, photoluminescent properties and absolute quantum yield of compound II were also investigated. The structure demonstrates that the crystal belongs to the triclinic system, space group P1 with a = 7.7339(3), b = 10.2396(5), c = 15.9076(8) ?, α = 76.517(4), β = 77.609(4), γ = 80.320(4)°, V = 1187.22(9) ?3, Z = 2, Dc = 1.514 g/mm3, μ = 4.901 mm-1, F(000) = 556.0, R = 0.0534 and w R = 0.1447(I > 2σ(I)). The result reveals that fluoroquionolone moiety in this structure stacks with π×××π interactions to generate an infinite 1D chain, which can stabilize the whole framework of compound II. Delightfully, preliminary antibacterial activity in vitro against 4 cell strains uncovers that compound II has almost equal strong activity in comparison with Clinafloxacin, but stronger than Norfloxacin. These outcomes provide important information for further exploration of the structure-activity relationship(SAR) of compound II derivatives or analogs.
A new compound 8-chloro-7- (4- (3-chloropropanoyl) piperazin-1 -yl) -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline- (20) H_ (20) Cl_2FN_3O_4, Mr = 456.08) was synthesized and characterized by 1H NMR, 13C NMR, HR MS and single-crystal X-ray diffraction Vis spectrum, photoluminescent properties and absolute quantum yield of compound II were also investigated. The structure demonstrates that the crystal belongs to the triclinic system, space group P1 with a = 7.7339 (3), b = 10.2396 (5), c = 15.9076 Β = 77.609 (4), γ = 80.320 (4) °, V = 1187.22 (9)? 3, Z = 2, Dc = 1.514 g / mm3, μ = 4.901 mm -1, F (000) = 556.0, R = 0.0534 and w R = 0.1447 (I> 2σ (I)). The result reveals that the fluoroquionolone moiety in this structure stacks with π ××× π interactions to generate an infinite 1D chain , which can stabilize the whole framework of compound II. Delightfully, preliminary antibacterial activity in vitro against 4 cell strains uncovers that compound II has almost equal strong activity in comparison with Clinafloxacin, but stronger than Norfloxacin. These outcomes provide important information for further exploration of the structure-activity relationship (SAR) of compound II derivatives or analogs.